A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Overview

About this study

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Diagnosis of UC for at least 3 months

- Moderately to severely active UC, assessed by mMS

- Inadequate response, loss of response to, or intolerance to conventional or advanced
therapies for UC

Exclusion Criteria:

- Diagnosis of Crohn's disease or indeterminate colitis

- Suspicion of ischemic, radiation, microscopic, or infectious colitis

- Prior colectomy

- Prior treatment with systemic janus kinase (JAK) inhibitors

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/8/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Edward Loftus, M.D.

Contact us for the latest status

Contact information:

Troy Ofstie R.N., CCRP

(507) 266-4728

IBDresearch@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20568026

Mayo Clinic Footer